AAPS Foundation announces 2015 new investigator grant and graduate student fellowship winners.
The AAPS Foundation announced on July 16 the 2015 New Investigator Grant andGraduate Student Fellowship winners selected from more than 125 applications from across the globe.
“There are few sources for start-up researcher funding dedicated to pharmaceutical sciences, and the AAPS Foundation is proud to support graduate PhD training and promoting the career development of young investigators through these competitive endowments,” noted Chair of the Graduate Student Fellowship and AAPS past-president Danny D. Shen. “The Graduate Student Fellowship award provides timely funding for students at the early to mid-stage of their graduate training, while the Investigator Grant is meant to support critical pilot studies to demonstrate the feasibility of a new and novel direction of research.”
AAPS Foundation New Investigator Grant Winner
The New Investigator Grant is a $40,000 grant awarded to a faculty member at a US institution to further innovative, impactful research. The award was presented to Anthony J. Kim, PhD, assistant professor of neurosurgery and pharmaceutical sciences at the University of Maryland for novel therapeutic strategies to target invasive brain cancer.
AAPS Foundation Graduate Student Fellowships
Graduate Student Fellowships recognize student excellence in their academic performance and validates that their research is deemed outstanding by an expert panel of outside pharmaceutical scientists. Awards were presented to five AAPS student members; each received $10,000.
Winners
James I. Andorko
University of Maryland
Impact of Degradable Polymers on Lymph Node Function and Systemic Immunity
Haiyan Dong
Fuzhou University, Fuzhou, China
The Architecture and Biological Function of Dual Cyclized Aptamer-Coated Nanomaterials: Enhanced Specificity and Theranostics with Multifunctional Primer-integrated Molecular Beacon for Capturing Circulating Tumor Cells and Metastasis Prevention
Madeline Krentz
University of Kentucky
Gene Expression Profiles Reveal Alternative Targets of Therapeutic Intervention for the Treatment of Drug-Resistant Non-Small Cell Lung Cancers
Laura Isabel Mosquera-Giraldo
Purdue University
A molecular perspective for the understanding of the effectiveness of cellulose polymers at inhibiting drug crystallization
Laura Northrup
University of Kansas
Tolerogenic adjuvants for antigen-specific treatment of multiple sclerosis
Honorable Mentions were awarded to five students:
Zhijin Chen
University of Missouri–Kansas City
Discovery and application of IGF2R-specific peptide for liver fibrosis therapy
Xiao Wen Guan
University of Buffalo, New Yorkâ¨
Monocarboxylate Transporters (MCT) as a Novel Therapeutic Target in Triple Negative Breast Cancer (TNBC) Treatment
Krystina Hessâ¨
University of Maryland
Self-Assembled Nucleic Acid Particles to Drive Immune Tolerance
Behnoush Khorsand-Sourkohiâ¨
University of Iowa
A Novel RNA Based Biomaterial for Bone Regeneration
Adil Rasheed
University of Toronto, Canadaâ¨
The modulation of endothelial progenitor cell function by the liver X receptors as a treatment for atherosclerosis
Source: American Association of Pharmaceutical Scientists (AAPS)
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.